Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132537 | 0.92 | PTGDR2 (0.36) | BTKBRD4TEAD1PTGDR2 | |
| SCHEMBL20554479 | 0.92 | PTGDR2 (0.36) | BTKBRD4TEAD1PTGDR2 | |
| SCHEMBL20554841 | 0.90 | TEAD1 (0.47) | BTKTEAD1SLC6A4PTGDR2TGM2 | |
| SCHEMBL20608867 | 0.84 | TRPV1 (0.36) | BTKTRPV1TEAD1KDM4CP2RX7 | |
| SCHEMBL19054502 | 0.81 | TEAD1 (0.47) | BTKTRPV1TEAD1PTGDR2TGM2 | |
| SCHEMBL30132663 | 0.81 | TEAD1 (0.47) | BTKTRPV1TEAD1PTGDR2TGM2 | |
| SCHEMBL20554707 | 0.80 | TEAD1 (0.47) | BTKTRPV1TEAD1SLC6A4PTGDR2 | |
| SCHEMBL20554332 | 0.80 | TEAD1 (0.35) | TRPV1TEAD1P2RX7 | |
| SCHEMBL20554045 | 0.80 | P2RX7 (0.37) | BRD4TEAD1PTGDR2P2RX7 | |
| SCHEMBL30132494 | 0.80 | P2RX7 (0.37) | BRD4TEAD1PTGDR2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770211-B | Alpha, beta unsaturated amide compound | 协和麒麟株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-108430972-B | Alpha, beta-unsaturated amide compound | 协和麒麟株式会社 | 2022-12-27 | — | — | CN | disclosed |
| US-11447471-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| US-11332455-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | KYOWA KIRIN CO., LTD. (JP) | 2021-05-27 | — | — | US | disclosed |
| US-10787428-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3712129-A1 | ALPHA, BETA-UNSATURATED AMIDE COMPOUND | Kyowa Kirin Co., Ltd. (JP) | 2020-09-23 | — | — | EP | disclosed |
| CN-110770211-A | α unsaturated amide compound | 协和麒麟株式会社 | 2020-02-07 | — | — | CN | disclosed |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3401309-A1 | a, ß UNSATURATED AMIDE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155612-A1 | Alpha,Beta-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, RXRA | BTK 2944/4885BRD4 859/4885TRPV1 1750/4885 |
| US-11447471-B2 | α,β-unsaturated amide compound | NR1H2, RXRA, RXRB | BTK 2864/4885BRD4 757/4885TRPV1 1595/4885 |
| US-10787428-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | BTK 2983/4885BRD4 555/4885TRPV1 1746/4885 |
| US-20210380551-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | BTK 3118/4885BRD4 674/4885TRPV1 1868/4885 |
| US-11332455-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | BTK 2983/4885BRD4 555/4885TRPV1 1746/4885 |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | BTK 3118/4885BRD4 674/4885TRPV1 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.